Introduction
Renal cell carcinoma (RCC) comprises approximately 3.8% of all new cancers, with a median age at diagnosis of 64 years. Approximately 90% of renal tumors are RCC, 80% of these are clearcell carcinomas [1, 2] . 20-30% of patients present with metastatic disease, and 20-40% of patients undergoing radical nephrectomy for localized disease will develop future metastases [3] . While several targeted therapies are approved for the treatment of metastatic RCC (mRCC), current markers typically provide prognostic information but are not known to be predictive [4] . Patients with mRCC treated with targeted therapy have been followed up with repeated imaging studies to evaluate the treatment response. Several studies demonstrate a prognostic and predictive role of plasma cytokines and angiogenic factors (CAFs) in patients with mRCC treated with targeted therapy [4, 5] . Despite existing data about predictive biomarkers there are still limitations to implicating them for daily practice. Future studies are needed to accumulate more clinical data for existing RCC markers and to search for new markers.
Circulating cell-free DNA (CFD) levels may be elevated in cancer and various other circumstances [6] . The presence of elevated levels of CFD in the blood of patients with cancer was initially described by Leon et al. [7] in 1977. Since then, many studies have described elevated CFD levels in patients with various malignancies [8] , including RCC [9] [10] [11] [12] . Circulating CFD levels originate from the release of DNA from cellular necrosis and apoptosis of tumor cells [13, 14] . An additional possible source of DNA in the circulation is active extrusion from immune cells. The release of neutrophil extracellular traps (NETs) has been identified as a mechanism of bacterial killing [12] .
Various complex techniques are currently in use to measure CFD concentrations, fragmentation, mutations, and epigenetic
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In the present study, we sought to prospectively evaluate the association between the CFD concentration and the treatment outcome of mRCC.
Patients and Methods

Study Group
The present study is a prospective study of patients with mRCC treated with targeted therapy in the Department of Oncology of the Soroka Medical Center, Beer Sheva, Israel, between 2013 and 2015. All patients had histologically confirmed RCC and objective disease progression before the initiation of targeted therapy. Patient follow-up generally consisted of regular physical examination and blood assessments every 4-6 weeks and imaging studies performed every 12-16 weeks.
Treatment Outcomes
Follow-up time was defined as the time from treatment initiation to September 30, 2016. For the evaluation of response, the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 were applied [16] . The response was assessed by independent radiologists and treating physicians. Progression-free survival (PFS) was defined as the time from the initiation of treatment until evidence of disease progression on scans or death of any cause. Overall survival (OS) was defined as the time from the initiation of treatment to death of any cause.
CFD Assay
Blood samples were collected from all patients for CFD level determination before treatment and at weeks 1, 4, 12, 18, and 24 of treatment. The serum was separated from the cellular fraction and frozen at -20 ° C until the CFD was quantified, as previously described, using our rapid SYBR ® Gold fluorometric assay [6] . The normal cut-off level of CFD was defined as 800 ng/ml (approximately 2 standard deviations from the mean of healthy subjects) [6] .
Statistical Analysis
Patients who did not progress or die by September 30, 2016, were censored in the PFS analysis or the OS analysis, respectively. In order to determine if the CFD concentration is independently associated with the treatment outcome, the entire patient cohort was analyzed by a univariate analysis (unadjusted) of association between clinicopathologic factors and the CFD concentration, and clinical outcome, using logistic regression for response rates and the Cox regression model for survival outcomes (PFS and OS). Factors with significant association in the univariate analysis were included in the multivariate Cox proportional hazards regression model to determine their independent effects. A p-value of 0.05 was considered statistically significant. Survival probabilities and median survival times were estimated from Kaplan-Meier curves. Clinicopathologic factors included in the analysis were age, gender, histology (clearcell vs. non-clear-cell carcinoma), past nephrectomy, previous systemic therapies, number of metastasis sites, presence of lung, liver, bone metastases, pretreatment neutrophil-to-lymphocyte ratio (NLR) > 3, the risk associated to the Heng prognostic model, pretreatment CFD levels, and CFD level during treatment. Data were analyzed using the SPSS software (SPSS for Windows).
Regulatory Considerations
The research was carried out in accordance with the approval by the institutional review board (IRB) committee of our institution.
Results
Patient Characteristics
Twenty-three patients were included in this study. 18 patients were treated with first-line therapy (sunitinib or pazopanib), and 5 patients, with second and third lines (axitinib or everolimus). The patients' characteristics are listed in table 1. The median age was 66 years; 70% were male. Of the 23 included patients, 87% (n = 20) had a clear-cell histology and 78% (n = 18) had a nephrectomy. 52% (n = 12) of the patients had baseline CFD elevation.
Treatment Outcome
The median follow-up was 16 months (range 4-37 months). The best response to therapy was complete response (CR) in 9% (n = 2), partial response (PR) in 9% (n = 2), stable disease (SD) in 52% (n = 12), and progressive disease (PD) in 30% (n = 7) (table 2). The median PFS was 12.7 months (range 3-37 months), and the median OS, 17.3 months (range 5-37 months).
Factors Associated with Response to Therapy
None of the following factors were associated with the response rate: age, gender, pretreatment NLR > 3, nephrectomy, histology, Heng risk, metastasis site, more than 1 metastasis site, pretreatment CFD level, and prior anti-angiogenic treatment.
Two patients had a CR with normal CFD levels (CFD-) before treatment and during the 24 weeks of treatment ( fig. 1 ). 2 patients with PR per RECIST guideline (version 1.1) had elevated CFD levels (CFD+) before treatment (2,870 and 1,344 ng/ml), which decreased to normal values following treatment ( fig. 2 ). 12 patients with SD had normal initial values (median 757 ng/ml, 95% confidence interval (CI) 614-1,052 ng/ml). 11 of these patients with SD had small changes in CFD during treatment ( fig. 3) . We excluded 1 CFD test result from the analysis due to hospitalization of the patient with pulmonary embolism; CFD levels are known to increase in pulmonary embolism. Seven patients with PD had elevated CFD concentrations before treatment initiation (median 1,016 ng/ml, 95% CI 425-2,624 ng/ml). In this group, we observed large fluctuations in the CFD levels, which were associated with short response to the treatment or disease progression as best response (fig. 4) .
Univariate Analysis of Factors Associated with PFS and OS
The following factors were individually associated with PFS (table 1): pretreatment CFD levels (normal vs. elevated: hazard ratio (HR) 3.36, p = 0.039) and the Heng risk (HR 22.1, p = 0.029). OS was associated with age (HR 0.28, p = 0.034) and more than 1 metastasis site (HR 0.66, p = 0.021).
Multivariate Analysis of Factors Associated with PFS and OS
The following factors were independently associated with PFS (table 1): pretreatment CFD levels (HR 4.55, p = 0.020) and the Heng risk (HR 64.6, p = 0.006). No factor was found to be independently associated with OS, including age (HR 1.05, p = 0.091) and more than 1 metastasis site (HR 3.54, p = 0.058). Patients with normal CFD levels before treatment had significant benefit in PFS versus patients with increased levels (p = 0.023).
Discussion
This is the fourth study based on our innovative and simple technique to measure CFD levels in cancer patients [17] [18] [19] . Various complex techniques have been used to evaluate CFD concentrations, fragmentation, mutations, and epigenetic changes in cancer patients, including RCC. Our assay eliminates the extraction phase, and DNA is measured directly in the diluted samples using the fluorochrome, SYBR ® Gold [6] . PFS = Progression-free survival, OS = overall survival, HR = hazard ratio, NLR = neutrophil-to-lymphocyte ratio, CFD = cell-free DNA. Elevated CFD levels in patients with RCC have been previously described in several studies. For example, Hauser et al. [9] measured it in 35 patients with RCC, by a quantitative real-time PCR assay, and reported an increase of the CFD levels in RCC patients versus healthy individuals. Lu et al. [12] measured genomic and mitochondrial CFD concentrations, by PCR, in 40 healthy people, 145 non-metastatic, and 84 metastatic clear-cell RCC patients. The mitochondrial CFD level was higher in metastatic than in nonmetastatic patients and controls. Ball et al. [20] detected circulating tumor DNA in only 1 out of 4 patients with RCC, by a next-generation sequencing method and digital PCR.
Tran et al. [4] identified the concentrations of circulating CAFs associated with clinical outcome. Patients treated with pazopanib for mRCC who had high concentrations of interleukin-8, osteopontin, hepatocyte growth factor, and tissue inhibitor of metalloproteinases had a significantly worse prognosis. The question whether the same markers predict benefit from other active drugs such as sunitinib or mammalian target of rapamycin (mTOR) inhibitors is still unresolved.
To the best of our knowledge, the association between CFD levels and the outcome of targeted therapy, in addition to the changes in CFD levels during therapy, in patients with mRCC has not been previously reported. The present study measured the CFD levels in patients with mRCC before treatment initiation and at weeks 1, 4, 12, 18, and 24 of treatment. We found that the CFD levels during treatment may be associated with a clinical benefit (CR + PR + SD). Patients with PD had large fluctuations in their CFD levels, which were associated with short response to treatment or disease progression. Furthermore, we also analyzed the association between CFD levels and PFS and OS and found that patients with normal pretreatment CFD levels may have a better PFS (p = 0.023).
Our study has some limitations. First, CFD elevation is not specific for RCC. Elevated CFD levels have been observed in patients with different types of malignancies [6] [7] [8] as well as nonmalignant etiologies, such as trauma, systemic inflammatory disorders, pulmonary embolism, and acute myocardial infarction [11] . Second, the present study cohort is small and heterogeneous (mixed first and advanced treatment lines) and, thus, in a larger and homogeneous cohort, other factors might have been associated with treatment outcome. Only 5 patients out of 23 were previously treated with anti-angiogenic regimens; therefore, we did not perform statistical analyses among treatment arms. Thus, a larger prospective study is warranted to test and confirm our hypothesis-generating study.
In conclusion, in patients with mRCC treated with targeted therapy, elevated pretreatment CFD may be associated with a worse PFS. The CFD level may also be associated with clinical benefit of therapy. Future trials are warranted to test our observation.
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